deforolimus

On the other hand, everolimus is in a tablet form, using the dose and schedule that they put forth which is a daily dose of 10mg a day, and so there the differentiation with ARIAD's product we are developing with Merck, namely deforolimus, is that our dose and schedule could not be more different.

SeekingAlpha.com: Home Page 2008

On the other hand, everolimus is in a tablet form, using the dose and schedule that they put forth which is a daily dose of 10mg a day, and so there the differentiation with ARIAD's product we are developing with Merck, namely deforolimus, is that our dose and schedule could not be more different.

SeekingAlpha.com: Home Page 2008

On the other hand, everolimus is in a tablet form, using the dose and schedule that they put forth which is a daily dose of 10mg a day, and so there the differentiation with ARIAD's product we are developing with Merck, namely deforolimus, is that our dose and schedule could not be more different.

Biotech Sector and Stocks Analysis from Seeking Alpha 2008

ARIAD Pharmaceuticals, Inc.: (NASDAQ: ARIA) today announced that new preclinical data on deforolimus:, its investigational mTOR inhibitor, AP24534:, its investigational multi-targeted kinase inhibitor, and its investigational anaplastic lymphoma kinase (ALK) inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado, being held

unknown title 2009

Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activityPresenter: Sriram Sathyanarayanan, Ph. D. (Merck & Co.)

unknown title 2009

The first interim analysis from this pivotal study of deforolimus, also known as AP23573, in patients with metastatic soft-tissue and bone sarcoma is driven by the number of progression events -- when a cancer starts growing or a patient dies -- that take place in the trial, but the company expects the analysis (at one-third of events) to take place later in the second quarter.

unknown title Adam Feuerstein 2009

ARIAD's lead product candidate, deforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co.,

unknown title 2009

#1887Title: The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancerPresenter: Brian Haines, Ph. D. (Merck & Co.)

unknown title 2009

Ariad will get an interim look at the phase 3 data at the end of this year, but unless deforolimus has a remarkable affect, the company will have to wait until next year to know if the drug works or not.

The Money Times - finance news, lifestyle, markets, investment, personal finance, banking, retirement planning Brian Orelli 2008

A substantial unmet medical need exists for the patients involved in these trials, creating a substantial commercial opportunity for novel molecularly targeted agents such as oral deforolimus.

Biotech Sector and Stocks Analysis from Seeking Alpha 2008